Wang Y - Search Results

1

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.

Jones L, Rittberg R, Leung B, Shokoohi A, Pender A, Wong S, Al-Hashami Z, Wang Y, Ho C. Jones L, et al. Among authors: wang y. Curr Oncol. 2022 Nov 15;29(11):8686-8692. doi: 10.3390/curroncol29110685. Curr Oncol. 2022. PMID: 36421338 Free PMC article.

2

Resource use in the last three months of life by lung cancer patients in southern Ontario.

Wang Y, Van Dam A, Slaven M, Ellis KJ, Goffin JR, Juergens RA, Ellis PM. Wang Y, et al. Curr Oncol. 2019 Aug;26(4):247-252. doi: 10.3747/co.26.4967. Epub 2019 Aug 1. Curr Oncol. 2019. PMID: 31548804 Free PMC article.

3

Update on systemic therapy for advanced soft-tissue sarcoma.

Smrke A, Wang Y, Simmons C. Smrke A, et al. Among authors: wang y. Curr Oncol. 2020 Feb;27(Suppl 1):25-33. doi: 10.3747/co.27.5475. Epub 2020 Feb 1. Curr Oncol. 2020. PMID: 32174755 Free PMC article. Review.

4

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.

Rittberg R, Leung B, Shokoohi A, Pender A, Wong S, Al-Hashami Z, Wang Y, Ho C. Rittberg R, et al. Among authors: wang y. Curr Oncol. 2023 May 26;30(6):5299-5308. doi: 10.3390/curroncol30060402. Curr Oncol. 2023. PMID: 37366885 Free PMC article.

5

Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years.

Silver A, Ho C, Ye Q, Zhang J, Janzen I, Li J, Martin M, Wu L, Wang Y, Lam S, MacAulay C, Melosky B, Yuan R. Silver A, et al. Among authors: wang y. Curr Oncol. 2023 Jun 8;30(6):5546-5559. doi: 10.3390/curroncol30060419. Curr Oncol. 2023. PMID: 37366902 Free PMC article. Clinical Trial.

6

Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer.

Li K, Bosdet I, Yip S, Ho C, Laskin J, Melosky B, Wang Y, Sun S. Li K, et al. Among authors: wang y. Curr Oncol. 2023 Jul 25;30(8):7099-7111. doi: 10.3390/curroncol30080515. Curr Oncol. 2023. PMID: 37622996 Free PMC article.

7

Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial.

Connor Wells J, Mullin MM, Ho C, Melosky B, Laskin J, Wang Y, Sun S. Connor Wells J, et al. Among authors: wang y. Lung Cancer. 2024 Apr;190:107529. doi: 10.1016/j.lungcan.2024.107529. Epub 2024 Mar 4. Lung Cancer. 2024. PMID: 38452600

8

Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer.

Tsang ES, Wong HL, Wang Y, Renouf DJ, Cheung WY, Lim HJ, Gill S, Loree JM, Kennecke HF. Tsang ES, et al. Among authors: wang y. Am J Clin Oncol. 2019 Feb;42(2):196-201. doi: 10.1097/COC.0000000000000500. Am J Clin Oncol. 2019. PMID: 30499841

9

Variations in Emergency Service Utilization among Cancer Survivors: Results from the Pan-Canadian Experiences of Cancer Patients in Transition Study Survey.

Delisle M, Wang Y, Fitch MI, Nagaratnam K, Srikanthan A. Delisle M, et al. Among authors: wang y. J Oncol. 2023 Mar 16;2023:5056408. doi: 10.1155/2023/5056408. eCollection 2023. J Oncol. 2023. PMID: 36968642 Free PMC article.

10

Clinical outcomes of brain metastasectomy from soft tissue and bone sarcomas: a systematic review.

Wang Y, Delisle M, Smith D, Alshamsan B, Srikanthan A. Wang Y, et al. Int J Clin Oncol. 2022 Nov;27(11):1767-1779. doi: 10.1007/s10147-022-02227-4. Epub 2022 Aug 22. Int J Clin Oncol. 2022. PMID: 35994183

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

272,308 results

Search Page